❌

Normal view

COMMA: A Communicative Multimodal Multi-Agent Benchmark

arXiv:2410.07553v5 Announce Type: replace Abstract: The rapid advances of multimodal agents built on large foundation models have largely overlooked their potential for language-based communication between agents in collaborative tasks. This oversight presents a critical gap in understanding their effectiveness in real-world deployments, particularly when communicating with humans. Existing agentic benchmarks fail to address key aspects of inter-agent communication and collaboration, particularly in scenarios where agents have unequal access to information and must work together to achieve tasks beyond the scope of individual capabilities. To fill this gap, we introduce COMMA: a novel puzzle benchmark designed to evaluate the collaborative performance of multimodal multi-agent systems through language communication. Our benchmark features a variety of multimodal puzzles, providing a comprehensive evaluation across four key categories of agentic capability in a communicative collaboration setting. Our findings reveal surprising weaknesses in state-of-the-art models, including strong proprietary models like GPT-4o and reasoning models like o4-mini. Many chain of thought reasoning models such as R1-Onevision and LLaVA-CoT struggle to outperform even a random baseline in agent-agent collaboration, indicating a potential growth area in their communication abilities.

The emerging role of microbiota in lung cancer: a new perspective on lung cancer development and treatment

Cell Oncol (Dordr). 2025 Aug 26. doi: 10.1007/s13402-025-01103-3. Online ahead of print.

ABSTRACT

Lung cancer remains the leading cause of cancer-related mortality worldwide, with limited treatment efficacy and frequent resistance to conventional therapies. Recent advances have uncovered the critical influence of the human microbiota-complex communities of bacteria, viruses, fungi, and other microorganisms-on lung cancer pathogenesis and therapeutic responses. This review synthesizes current knowledge on the compositional and functional roles of microbiota across multiple body sites, including the gut, lung, tumor microenvironment, circulation, and oral cavity, highlighting their contributions to tumor initiation, progression, metastasis, and immune regulation. We emphasize the bidirectional communication between microbial metabolites and host immune pathways, particularly the gut-lung axis, which modulates systemic and local antitumor immunity. Importantly, microbiota composition has been linked to differential responses and toxicities in chemotherapy, radiotherapy, targeted therapy, and immune checkpoint blockade. Microbiota-targeted interventions, such as probiotics, fecal microbiota transplantation, and selective antibiotics, show promising potential to enhance treatment efficacy and mitigate adverse effects. However, challenges remain in clinical translation due to interindividual microbiome variability, mechanistic complexities, and limited longitudinal data. Future research integrating multi-omics, microbial functional profiling, and controlled clinical trials is essential to harness the microbiome as a precision medicine tool in lung cancer management. This review provides a comprehensive overview of the emerging role of microbiota in lung cancer development and therapy, offering new perspectives for innovative therapeutic strategies.

PMID:40856929 | DOI:10.1007/s13402-025-01103-3

❌